Market Research Logo

Radiation Toxicity - Pipeline Review, H1 2017

Radiation Toxicity - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals Inc
Angion Biomedica Corp
Atox Bio Ltd
BCN Biosciences LLC
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Cellphire Inc
Chrysalis BioTherapeutics Inc
Cleveland BioLabs Inc
Daiichi Sankyo Company Ltd
FirstString Research Inc
Foresee Pharmaceuticals LLC
Galera Therapeutics Inc
Genzyme Corp
GNI Group Ltd
Humanetics Corp
Insys Therapeutics Inc
Meabco A/S
Neumedicines Inc
Nohla Therapeutics Inc
Onconova Therapeutics Inc
Original BioMedicals Co Ltd
PharmaIN Corp
Pluristem Therapeutics Inc
RDD Pharma Ltd
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
RxBio Inc
Shuttle Pharmaceuticals LLC
SK Chemicals Co Ltd
Soligenix Inc
Synedgen Inc
Tonix Pharmaceuticals Holding Corp
TSRL Inc
viDA Therapeutics Inc
Windtree Therapeutics Inc
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile
A-02 - Drug Profile
AB-103 - Drug Profile
ABC-294640 - Drug Profile
AEOL-10171 - Drug Profile
Aerosurf - Drug Profile
amifostine - Drug Profile
amifostine - Drug Profile
AVMOC-001 - Drug Profile
BB-3 - Drug Profile
BBT-007 - Drug Profile
BBT-015 - Drug Profile
BBT-018 - Drug Profile
BBT-059 - Drug Profile
BCN-057 - Drug Profile
BIO-300 - Drug Profile
BMX-001 - Drug Profile
BPC-2 - Drug Profile
C-2E2 - Drug Profile
C-2E5 - Drug Profile
Cell Therapy for Acute Radiation Syndrome - Drug Profile
cerium oxide - Drug Profile
CLT-009 - Drug Profile
Des-Asp Angiotensin 1 - Drug Profile
DG-3 - Drug Profile
entolimod - Drug Profile
EWA-001 - Drug Profile
Fibrinoplate-S - Drug Profile
FP-045 - Drug Profile
Granexin - Drug Profile
HSJ-0017 - Drug Profile
JP4-039 - Drug Profile
LGM-2605 - Drug Profile
m-2A2 - Drug Profile
MDY-1001 - Drug Profile
molgramostim - Drug Profile
NAS-911 - Drug Profile
NMIL-121 - Drug Profile
omaveloxolone - Drug Profile
ondansetron hydrochloride - Drug Profile
ondansetron hydrochloride CR - Drug Profile
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
pirfenidone - Drug Profile
PLXR-18 - Drug Profile
Preimplantation Factor - Drug Profile
QR-205 - Drug Profile
RDD-2007 - Drug Profile
recilisib sodium - Drug Profile
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
RP-239X - Drug Profile
RS-9 - Drug Profile
rusalatide acetate - Drug Profile
Rx-100 - Drug Profile
sargramostim - Drug Profile
SGX-201 - Drug Profile
SGX-202 - Drug Profile
SKI-2162 - Drug Profile
Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile
Small Molecule for Radiation Toxicity - Drug Profile
Small Molecule for Radiation Toxicity 1 - Drug Profile
Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
SP-3001 - Drug Profile
ST-266 - Drug Profile
ST-7 - Drug Profile
SY-513 - Drug Profile
SYGN-305 - Drug Profile
SYGN-399 - Drug Profile
Thrombosomes - Drug Profile
TNX-701 - Drug Profile
TPO-7630 - Drug Profile
TPO-7640 - Drug Profile
VEDA-1209 - Drug Profile
VTI-1000 Series - Drug Profile
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report